BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Vilaseca M, Guixé-Muntet S, Fernández-Iglesias A, Gracia-Sancho J. Advances in therapeutic options for portal hypertension. Therap Adv Gastroenterol 2018;11:1756284818811294. [PMID: 30505350 DOI: 10.1177/1756284818811294] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 3.5] [Reference Citation Analysis]
Number Citing Articles
1 Rodrigues SG, Mendoza YP, Bosch J. Investigational drugs in early clinical development for portal hypertension. Expert Opin Investig Drugs 2022. [PMID: 35758843 DOI: 10.1080/13543784.2022.2095259] [Reference Citation Analysis]
2 Gibert-Ramos A, Sanfeliu-Redondo D, Aristu-Zabalza P, Martínez-Alcocer A, Gracia-Sancho J, Guixé-Muntet S, Fernández-Iglesias A. The Hepatic Sinusoid in Chronic Liver Disease: The Optimal Milieu for Cancer. Cancers (Basel) 2021;13:5719. [PMID: 34830874 DOI: 10.3390/cancers13225719] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
3 Turaga RC, Satyanarayana G, Sharma M, Yang JJ, Wang S, Liu C, Li S, Yang H, Grossniklaus H, Farris AB, Gracia-Sancho J, Liu ZR. Targeting integrin αvβ3 by a rationally designed protein for chronic liver disease treatment. Commun Biol 2021;4:1087. [PMID: 34531529 DOI: 10.1038/s42003-021-02611-2] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
4 Bochnakova T. Hepatic Venous Pressure Gradient. Clin Liver Dis (Hoboken) 2021;17:144-8. [PMID: 33868655 DOI: 10.1002/cld.1031] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 7.0] [Reference Citation Analysis]
5 Alqahtani SA, Jang S. Pathophysiology and Management of Variceal Bleeding. Drugs 2021;81:647-67. [PMID: 33710585 DOI: 10.1007/s40265-021-01493-2] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
6 Yoshida H, Shimizu T, Yoshioka M, Taniai N. Management of portal hypertension based on portal hemodynamics. Hepatol Res 2021;51:251-62. [PMID: 33616258 DOI: 10.1111/hepr.13614] [Reference Citation Analysis]
7 Guixé-muntet S, Zhu C, Xie W, Gracia-sancho J. Novel therapeutics for portal hypertension and fibrosis in chronic liver disease. Pharmacology & Therapeutics 2020;215:107626. [DOI: 10.1016/j.pharmthera.2020.107626] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
8 Boyer-Diaz Z, Morata P, Aristu-Zabalza P, Gibert-Ramos A, Bosch J, Gracia-Sancho J. Oxidative Stress in Chronic Liver Disease and Portal Hypertension: Potential of DHA as Nutraceutical. Nutrients 2020;12:E2627. [PMID: 32872239 DOI: 10.3390/nu12092627] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
9 Nevzorova YA, Boyer-diaz Z, Cubero FJ, Gracia-sancho J. Animal models for liver disease – A practical approach for translational research. Journal of Hepatology 2020;73:423-40. [DOI: 10.1016/j.jhep.2020.04.011] [Cited by in Crossref: 37] [Cited by in F6Publishing: 62] [Article Influence: 18.5] [Reference Citation Analysis]
10 Ortega-Ribera M, Hunt NJ, Gracia-Sancho J, Cogger VC. The Hepatic Sinusoid in Aging and Disease: Update and Advances From the 20th Liver Sinusoid Meeting. Hepatol Commun 2020;4:1087-98. [PMID: 32626839 DOI: 10.1002/hep4.1517] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
11 Møller S, Kimer N, Barløse M, Bendtsen F. Pathophysiological-based treatments of complications of cirrhosis. Scand J Gastroenterol 2020;55:383-94. [PMID: 32233873 DOI: 10.1080/00365521.2020.1744709] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
12 Mandorfer M, Kozbial K, Schwabl P, Chromy D, Semmler G, Stättermayer AF, Pinter M, Hernández-Gea V, Fritzer-Szekeres M, Steindl-Munda P, Trauner M, Peck-Radosavljevic M, García-Pagán JC, Ferenci P, Reiberger T. Changes in Hepatic Venous Pressure Gradient Predict Hepatic Decompensation in Patients Who Achieved Sustained Virologic Response to Interferon-Free Therapy. Hepatology 2020;71:1023-36. [PMID: 31365764 DOI: 10.1002/hep.30885] [Cited by in Crossref: 70] [Cited by in F6Publishing: 68] [Article Influence: 35.0] [Reference Citation Analysis]
13 Boyer-Diaz Z, Domingo JC, De Gregorio E, Manicardi N, Aristu-Zabalza P, Cordobilla B, Abad-Jordà L, Ortega-Ribera M, Fernández-Iglesias A, Marí M, Bosch J, Gracia-Sancho J. A Nutraceutical Rich in Docosahexaenoic Acid Improves Portal Hypertension in a Preclinical Model of Advanced Chronic Liver Disease. Nutrients 2019;11:E2358. [PMID: 31623374 DOI: 10.3390/nu11102358] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 3.7] [Reference Citation Analysis]
14 Bunchorntavakul C, Reddy KR. Pharmacologic Management of Portal Hypertension. Clin Liver Dis 2019;23:713-36. [PMID: 31563219 DOI: 10.1016/j.cld.2019.06.004] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
15 Mandorfer M, Hernández-gea V, Reiberger T, García-pagán JC. Hepatic Venous Pressure Gradient Response in Non-Selective Beta-Blocker Treatment—Is It Worth Measuring? Curr Hepatology Rep 2019;18:174-86. [DOI: 10.1007/s11901-019-00469-x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 5.0] [Reference Citation Analysis]
16 Gracia-Sancho J, Manicardi N, Ortega-Ribera M, Maeso-Díaz R, Guixé-Muntet S, Fernández-Iglesias A, Hide D, García-Calderó H, Boyer-Díaz Z, Contreras PC, Spada A, Bosch J. Emricasan Ameliorates Portal Hypertension and Liver Fibrosis in Cirrhotic Rats Through a Hepatocyte-Mediated Paracrine Mechanism. Hepatol Commun 2019;3:987-1000. [PMID: 31304452 DOI: 10.1002/hep4.1360] [Cited by in Crossref: 7] [Cited by in F6Publishing: 21] [Article Influence: 2.3] [Reference Citation Analysis]